BONUSCAP-ZERTIFIKAT - FRESENIUS MEDICAL CARE Share Price

Certificat

DE000HC9EFS2

Real-time BOERSE MUENCHEN 05:16:10 04/06/2024 pm IST
39.24 EUR +0.26% Intraday chart for BONUSCAP-ZERTIFIKAT - FRESENIUS MEDICAL CARE
Current month-0.20%
1 month+2.17%
Date Price Change
04/24/04 39.24 +0.26%
03/24/03 39.14 -0.20%
31/24/31 39.22 +0.59%
30/24/30 38.99 +1.54%
29/24/29 38.4 -2.24%

Real-time BOERSE MUENCHEN

Last update June 04, 2024 at 05:16 pm IST

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying FRESENIUS MEDICAL CARE AG
IssuerLogo Issuer UniCredit UniCredit
WKN HC9EFS
ISINDE000HC9EFS2
Date issued 22/09/2023
Strike 60
Maturity 21/06/2024 (17 Days)
Parity 1 : 1
Emission price 45.88
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 46.17
Lowest since issue 30.32

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
39.25 EUR
Average target price
39.97 EUR
Spread / Average Target
+1.84%
Consensus